Last reviewed · How we verify
NCT05118074
Nova Max Creatinine and eGFR Meter System
trial testing Creatinine, eGFR in Chronic Kidney Diseases in 360 participants. Completed in 15 April 2024.
15 April 2024
Quick facts
| Lead sponsor | Nova Biomedical |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 360 |
| Start date | 8 June 2021 |
| Primary completion | 15 April 2024 |
| Estimated completion | 15 April 2024 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Creatinine, eGFR
Conditions studied
- Chronic Kidney Diseases — all drugs for Chronic Kidney Diseases →
- Acute Kidney Injury — all drugs for Acute Kidney Injury →
Sponsor
Nova Biomedical
Who can join
18 and older, any sex, with Chronic Kidney Diseases or Acute Kidney Injury. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To assess the performance of the Nova Max Creatinine and eGFR assay in the hands of CLIA-Waived Point-of-Care users in at least three (3) distinct Point-of-Care clinical settings on venous, and capillary blood and compare the performance characteristics to a traceable laboratory reference method (the Siemens EXL creatinine determination). To assess the Ease of Use of the Nova Max Creatinine and eGFR Meter System in the hands of the intended CLIA-Waived Point-of-Care users.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05118074
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Chronic Kidney Diseases
Currently open trials in the same condition.
- NCT06593392 — Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus · Phase 2 · recruiting
- NCT07358572 — Eye-Brain-Kidney in CKD · recruiting
- NCT06463483 — Automated Insulin Delivery in Adults With Advanced Kidney Disease · NA · recruiting
- NCT06927024 — Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD) · NA · recruiting
- NCT07115953 — Streamlined Denervation With spYral For an Optimized Treatment (SPYRAL SWYFT) in Subjects With Uncontrolled Hypertension · NA · recruiting
Other Nova Biomedical trials
Trials by the same sponsor.
- NCT04194476 — Performance Study of Nova StatStrip® Blood Glucose Monitoring Test System on Neonatal Capillary Blood · NA · suspended
- NCT05118061 — StatStrip Glucose/Ketone Meter System Ketone Evaluation · completed
- NCT05144971 — StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation · completed
- NCT05118048 — StatStrip Lactate, Hemoglobin, and Hematocrit Meter in Whole Blood · terminated
- NCT04096313 — Evaluation of the Analytical Performance of ALLEGRO™ Instrument · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05118074 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nova Biomedical
- Last refreshed: 13 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05118074.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing